Abstract
Emicizumab is a recombinant, humanized, and a bispecific monoclonal antibody that bridges activated factor (F) IX and FX in place of FVIII to restore hemostasis in persons with hemophilia A (PHA). Data on the efficacy and safety of emicizumab in young children is limited. Immunologic naivety, physiologically decreased production of vitamin K dependent proteins, specifically FIX, and enhanced clearance of emicizumab in infants may support decreased emicizumab effectiveness. We report on the facilitation of care rendered by using emicizumab in young PHA with inhibitors and extend data on the efficacy and safety in PHA < 3 years.
Original language | English (US) |
---|---|
Article number | e28942 |
Journal | Pediatric Blood and Cancer |
Volume | 68 |
Issue number | 5 |
DOIs | |
State | Published - May 2021 |
Keywords
- emicizumab
- hemophilia A
- infant
- inhibitor
- toddler
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology